Literature DB >> 7852429

Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1.

T Z Kirk1, M E Mark, C C Chua, B H Chua, M D Mayes.   

Abstract

Cultured fibroblasts derived from skin biopsies from scleroderma patients and normal individuals were examined for the presence of smooth muscle alpha-actin, a marker for myofibroblasts. Six of eight scleroderma cell lines were found to be 50% or more positive for alpha-actin while three of four normal lines and one cell line derived from unaffected skin of a scleroderma patient were less than 10% positive. The cultured fibroblasts from affected scleroderma skin were largely myofibroblasts, a phenotype found in biopsies of scleroderma tissue, as well as other fibrotic lesions, wound healing, and tumor desmoplasia. The data support the hypothesis that a certain activated fibroblast phenotype predominates in scleroderma. The activated fibroblast is the myofibroblast. Both collagen and TIMP (tissue inhibitor of metalloproteinases) were elevated in the alpha-actin positive (myofibroblast enriched) cultures. In addition, the myofibroblast-enriched cultures displayed a more prominent TIMP doublet band pattern on SDS-polyacrylamide gel electrophoresis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852429     DOI: 10.1074/jbc.270.7.3423

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis.

Authors:  B Eckes; D Kessler; M Aumailley; T Krieg
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

3.  Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Authors:  Francesco Del Galdo; M Alexander Shaw; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

4.  Enhanced neointimal fibroblast, myofibroblast content and altered extracellular matrix composition: Implications in the progression of human peripheral artery restenosis.

Authors:  Prakash Krishnan; K-Raman Purushothaman; Meerarani Purushothaman; Irene C Turnbull; Arthur Tarricone; Miguel Vasquez; Sachin Jain; Usman Baber; Rheoneil A Lascano; Annapoorna S Kini; Samin K Sharma; Pedro R Moreno
Journal:  Atherosclerosis       Date:  2016-06-30       Impact factor: 5.162

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 6.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

Review 7.  Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation.

Authors:  K Sobue; K Hayashi; W Nishida
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

Review 8.  Matrix remodeling in systemic sclerosis.

Authors:  Andrew Leask
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

Review 9.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

10.  Persistence of TGF-beta1 induction of increased fibroblast contractility.

Authors:  X D Liu; T Umino; R Ertl; T Veys; C M Skold; K Takigawa; D J Romberger; J R Spurzem; Y K Zhu; T Kohyama; H Wang; S I Rennard
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.